Side-effect free RNA therapeutics active only in diseased cells

SRTD biotech secures seed financing

18-Nov-2024 - Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient ...

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX

15-Jul-2024 - HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture ...

Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

DT-001 holds promise to be a game-changing treatment option for a broad range of autoimmune diseases

22-May-2023 - Dualyx NV, a Ghent based biotech developing next generation immune modulators, announces that it has completed a €40 million ($44 million) Series A financing. The fundraise has been co-led by Fountain Healthcare Partners, Forbion and Andera Partners, with support from existing investors V-Bio ...

FundaMental Pharma launches with EUR 10 million in Seed financing to advance a First-in-Class neuroprotectant

"These inhibitors have the potential to revolutionize therapies for currently untreatable neurodegenerative diseases"

21-Nov-2022 - FundaMental Pharma GmbH, a preclinical neuroscience company spun out of Heidelberg University, announces that it has launched with EUR 10 million in seed financing led by BioGeneration Ventures (BGV) and Thuja Capital, with participation from other investors, including coparion and High-Tech ...

Pioneering TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases

Kupando raises €13 million in Series A funding round

27-Sep-2022 - Kupando, a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases, announces today the closing of its Series A funding round which raised €13 million. The funds will be used to complete IND-enabling work and to ...

Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs  

13-Jan-2022 - Pantherna Therapeutics announces the successful completion of a follow-on financing round totaling EUR 4.0 Mio. led by existing investors Riesner Verwaltungs GmbH and High-Tech Gründerfonds. The proceeds of this round will be used to accelerate preclinical development activities for its lead ...

“Death complex” in neurons discovered

Novel compounds that act as molecular spacers in the brain prevent neurodegeneration

29-Jun-2021 - High-Tech Gründerfonds (HTGF) provides seed funding for the neuro start-up FundaMental Pharma GmbH (FMP), a spin-off of the Interdisciplinary Center for Neuroscience (IZN) at Heidelberg University. FMP scientists have discovered a “death complex” in neurons whose activation leads to ...

Advance Gene Therapy Pipeline for Musculoskeletal Diseases

GeneQuine Biotherapeutics Secures more than €9 Million

28-Jan-2021 - GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for musculoskeletal disorders, announced that it has raised €5.4 million in Series A financing and €3.65 million non-dilutive funding bringing the total amount raised to €9.05 million. The Series A ...

Gilead Sciences to Acquire MYR GmbH

One of the largest trade sales of a VC-financed German biotech start-up in the last 20 years - first HTGF unicorn

11-Dec-2020 - Gilead Sciences, Inc. and MYR GmbH announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 bn in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €0.3 bn million (both ...

Start-up receives €24 million for the development of a potential COVID-19 treatment

EIB backs Atriva Therapeutics

22-Oct-2020 - The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement to facilitate the company’s development and clinical testing of a novel therapy treating ...